|
|
Volumn 12, Issue 12, 2013, Pages 891-893
|
|
Learning from the 2012-2013 class of breakthrough therapies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3,4 DIAMINOPYRIDINE;
ABT 267;
ABT 333;
ABT 450;
ALECTINIB;
ANTINEOPLASTIC AGENT;
ANTISENSE OLIGONUCLEOTIDE;
ANTIVIRUS AGENT;
ASFOTASE ALFA;
ASUNAPREVIR;
BIMAGRUMAB;
BMS 791325;
DACLATASVIR;
DARATUMUMAB;
DRISAPERSEN;
ENTINOSTAT;
IBRUTINIB;
IVACAFTOR;
LDK 378;
LEDIPASVIR;
LUMACAFTOR;
MK 3475;
OBINUTUZUMAB;
OFATUMUMAB;
PALBOCICLIB;
SEBELIPASE ALFA;
SERELAXIN;
SOFOSBUVIR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VOLASERTIB;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE HEART FAILURE;
BREAST CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
CYSTIC FIBROSIS;
DRUG APPROVAL;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG TARGETING;
DUCHENNE MUSCULAR DYSTROPHY;
EATON LAMBERT SYNDROME;
ENZYME REPLACEMENT;
EXPERIMENTAL MEDICINE;
FOOD AND DRUG ADMINISTRATION;
HEPATITIS C;
HUMAN;
HYPOPHOSPHATASIA;
INCLUSION BODY MYOSITIS;
LUNG NON SMALL CELL CANCER;
MANTLE CELL LYMPHOMA;
MELANOMA;
MULTIPLE MYELOMA;
NOTE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
PUBLISHING;
WALDENSTROEM MACROGLOBULINEMIA;
WOLMAN DISEASE;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
COMMUNICABLE DISEASES;
DRUG APPROVAL;
DRUG DISCOVERY;
HUMANS;
NEOPLASMS;
UNITED STATES;
|
|
EID: 84889602851
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4196 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
